Physician profile
Karen C Mitchell
NPI 1619986114
$3,347.33
in general payments reported to CMS, 2019-2025
23 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 77% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $133 · 2021: $159 · 2022: $195 · 2023: $598 · 2024: $699 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,227 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.05 |
| Education | $281.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $543.95 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $468.11 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $373.49 | 2019-2025 | Adbry |
| Abbvie INC. | $315.55 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $287.66 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $265.94 | 2023-2025 | Ilumya |
| Ucb, INC. | $154.23 | 2024-2025 | Bimzelx |
| Revance Therapeutics, INC. | $145.68 | 2025 | Daxxify |
| Avanos Medical | $124.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $114.67 | 2024-2025 | |
| Genzyme Corporation | $98.47 | 2021-2025 | |
| Amgen INC. | $83.17 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $67.44 | 2024-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $53.59 | 2024-2025 | Zoryve |
| Botanix Sb INC | $43.36 | 2025 | Sofdra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $38.00 | 2023-2024 | Vtama |
| Dermira, INC. | $28.72 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.42 | 2025 | Givlaari |
| Incyte Corporation | $28.42 | 2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $23.75 | 2020 | |
| Organogenesis INC. | $20.73 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.38 | 2020 | |
| Almirall LLC | $18.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.